Environmental Stock Price, News & Analysis

GreenLight Biosciences (Nasdaq: GRNA) and EpiVax Therapeutics have entered an exclusive collaboration to develop personalized mRNA cancer vaccines. This partnership merges GreenLight's mRNA manufacturing expertise with EpiVax's advanced Ancer® technology for neo-antigen design. EpiVax will utilize its immunoinformatics tools to identify potent neo-antigens, while GreenLight will focus on mRNA formulation and production. Both companies aim to leverage their strengths for innovative oncology solutions, enhancing their cancer vaccine pipeline.

GreenLight Biosciences Holdings (GRNA) reported operational highlights and financial results for Q3 2022, recognizing a net loss of $38.2 million, up from $29.2 million YoY. Cash and equivalents stood at $98.4 million, projected to last until Q2 2023. The company is advancing its mRNA platform for COVID-19 and shingles vaccines, and plans to launch Calantha™, a novel crop protection solution, in 2023 pending EPA approval. A strategic realignment has led to a 25% workforce reduction, expected to save ~$13 million in direct employee costs in 2023.

GreenLight Biosciences (Nasdaq: GRNA) announced participation in two investor conferences on November 8, 2022. The Credit Suisse 31st Annual Healthcare Conference will feature a virtual presentation accessible on their investor relations website. Concurrently, GreenLight will attend the Baird Global Industrial Conference 2022 in Chicago, where CEO Dr. Andrey Zarur and CFO Susan Keefe will hold one-on-one meetings with investors. GreenLight focuses on leveraging RNA technology for advancements in human health and agriculture.

GreenLight Biosciences (Nasdaq: GRNA) announced a realignment to enhance operational efficiency and extend its cash runway. The company will focus on integrating teams for human and plant health, leading to a 25% workforce reduction. Recent advancements include partnerships with Samsung Biologics for mRNA manufacturing and collaborations with the NIH for vaccine development. GreenLight's plant team has achieved effective field control of fungal pathogens and is progressing on RNA seed treatments. The restructuring is expected to save approximately $13 million in employee costs in 2023.

GreenLight Biosciences has partnered with Queensland University of Technology (QUT) to develop an environmentally-friendly solution for the fall armyworm, a major agricultural pest responsible for over US$2 billion in annual global crop losses. Supported by a AUD$400,000 grant from the Australian government, the collaboration aims to harness RNA-based technologies to combat the pest. The project will commence with laboratory studies and progress to greenhouse and field trials, enhancing Australia's agricultural capacity and addressing global food production challenges.

GreenLight Biosciences (Nasdaq: GRNA) has raised $108.4 million in a private placement led by S2G Ventures, with funds aimed at supporting key programs through the first half of 2023. The company and Samsung Biologics completed a commercial-scale mRNA COVID-19 vaccine engineering run, working with partners like NIH and Serum Institute of India on various health initiatives. Anticipated milestones include EPA approval for Calantha™ by year-end. However, the company reported a net loss of $51.9 million for Q2 2022, up from $27.2 million a year earlier.

GreenLight Biosciences (Nasdaq: GRNA) announced a private placement raising approximately $109 million. This funding will support the launch of Calantha™, the first RNA solution for crop protection, and the development of vaccines targeting COVID-19 and shingles. The financing includes support from notable investors such as S2G Ventures and BNP Paribas. The company aims to enhance its research and commercial programs and has sufficient funds to operate through the first half of 2023. GreenLight has sold approximately 27.8 million shares at $3.92 each to institutional and accredited investors.

GreenLight Biosciences (Nasdaq: GRNA) and Samsung Biologics announced the successful completion of their first commercial-scale mRNA production run, taking only seven months for technology transfer and scale-up. The mRNA synthesis achieved a titer of 12g/L, producing 650g of mRNA using standard equipment. This partnership allows the production of both Drug Substance and LNP formulation in one facility. GreenLight plans to begin clinical trials for its Covid booster vaccine in 2022, demonstrating its capability to supply mRNA vaccines at a commercial scale.

GreenLight Biosciences has partnered with the National Institutes of Health (NIH) to develop innovative COVID-19 vaccines that provide broader protection against emerging variants and promote longer-lasting immunity. The collaboration aims to use GreenLight's mRNA platform alongside the Vaccine Research Center at NIH to enhance vaccine efficacy. Current vaccines face challenges due to ongoing virus mutations, making rapid development of new vaccines essential for public health. This partnership represents a significant advancement in the fight against COVID-19, focusing on developing vaccines active against various coronaviruses.